A retrospective, multicenter case series study of Pseudomonas Aeruginosa Infections Treated with Imipenem-Cilastatin-Relebactam
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Aug 2022 New trial record
- 13 Jun 2022 Results presented at the ASM Microbe 2022